Delveinsight

NOVEMBER 29, 2020

Key players such as Novartis , Annexin Pharmaceuticals , Gene Signal , Ocular Therapeutics , and Asclepix Therapeutics along with other pharma companies are investigating their candidates proactively in a quest to launch their therapies as soon as possible in the Retinal vein occlusion market.

Marketing 52

Marketing Drug Delivery Pharma Companies Clinical Trials 52

Delveinsight

AUGUST 17, 2020

Metoclopramide , sold under the brand name Reglan , is the first and only FDA-approved therapy for the treatment of Diabetic Gastroparesis. However, the drug is not FDA-approved but is available in some European countries. FDA for a phase 2b study in diabetic kidney disease (DKD).

Marketing 54

Marketing Trials FDA Approval Clinical Development 54

pharmaphorum

OCTOBER 10, 2021

ChemoCentryx has claimed FDA approval for its avacopan drug for a rare autoimmune disease, becoming the first orally-active drug that targets the complement C5 receptor. Avacopan is already approved in Japan for ANC vasculitis, which causes inflammation in organs including the kidneys, but is sold there by Kissei Pharma.

FDA Approval 52

FDA Approval Drugs Pharma Companies Clinical Trials 52

pharmaphorum

DECEMBER 23, 2020

There was some steady progress in neurology – in February FDA approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. months, compared with 6.7

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Delveinsight

AUGUST 2, 2020

Helsinn Group , a Swiss pharma player, is evaluating Anamorelin, an orally active selective ghrelin receptor agonist against Cancer cachexia, The company is conducting Phase III trial to test the efficacy and safety of anamorelin for the treatment of weight loss and anorexia in patients with advanced NSCLC with cachexia.

Marketing 94

Marketing Pharma Companies Development Hormones 94

XTalks

MAY 25, 2021

Biosimilar and interchangeable products can expand treatment options and lower drug and healthcare costs by offering a cheaper alternative with the same effectiveness; essentially a non-branded version of a biologic such as monoclonal antibodies, proteins and vaccines. million in 2019, according to Fortune Business Insights.

Production 98

Production Drugs Marketing Sales 98

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Last year, the company signed two deals in quick succession, which saw it form a licensing deal worth $1.3 The drug was added to Novartis’ portfolio through a $2.1

Manufacturing 105

Manufacturing Development Antibody Drugs 105

XTalks

MAY 29, 2024

Here, we will deep-dive into the top five fastest growing pharma and biotech companies in 2024, showcasing their innovative strategies and inspiring achievements. Pfizer (Overall Rank 268) Leading the list is one of the most renowned pharma companies in the world: Pfizer.

Medicine 52

Medicine Marketing FDA Approval Development 52

XTalks

JUNE 25, 2024

In the past two years, the industry has faced considerable challenges due to a constrained financing environment, forcing many emerging and early-stage biotech companies to restructure their operations, merge with other companies or narrow their research and development (R&D) efforts by shelving certain assets. billion in 2023.

Pharma Companies 52

Pharma Companies Production FDA Approval Vaccination 52

pharmaphorum

OCTOBER 27, 2021

The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Hargreaves. The monoclonal antibody was the first new drug to be approved for Alzheimer’s since 2003.

Clinical Trials 75

Clinical Trials Clinical Trials Research Trials 75

XTalks

MAY 29, 2024

The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

XTalks

AUGUST 17, 2020

Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. The design of the immune biologic puts these elements together on an antibody scaffold. Image from Cue Biopharma.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

FEBRUARY 11, 2025

billion Company/developer: Gilead Sciences Date of first FDA approval: February 7, 2018 FDA-approved indications: HIV-1 Price of Biktarvy: The list price of Biktarvy is $4,216 per month. billion in total sales for 2022, the most ever reported by any pharma company in a single year.

Sales 66

Sales FDA Approval Vaccination Vaccine 66